A therosclerosis was once considered a lipid storage disease. However, it is now recognized as a chronic and progressive inflammatory disease of the arterial intima. Although perturbations in cholesterol metabolism influence lesion development, progression of atherosclerosis is largely dependent on immune cells, particularly macrophages and T cells that promote inflammation by secreting proinflammatory cytokines. 1 Toll-like receptors (TLRs) are a family of pattern recognition receptors that enable the innate immune system to recognize and respond to invading pathogens. 2 They also detect endogenous host danger signals in the context of cancer metastasis 3 and chronic inflammation, 4 including atherosclerosis. 2 TLR involvement in atherosclerotic lesion development was initially shown using mice lacking MyD88, an intracellular adaptor protein involved in TLR signal transduction. 5 Such mice displayed reduced lesion severity in the apolipoprotein E-deficient (ApoE −/− ) mouse model. 6 Moreover, both TLR2 and TLR4, which are expressed on the surface of many cell types, including smooth muscle cells, endothelial cells, macrophages, and dendritic cells (DCs), have also been shown to be proatherogenic in the mouse, via mechanisms that include augmented T helper (Th) 1 cytokine secretion 6, 7 and, in the case of TLR4, modulation of plasma cholesterol levels. 8 Along with TLR4, TLR6 has also been implicated in promoting atherogenesis via initiation of inflammation in response to oxidized low-density lipoprotein (LDL). 4 Conversely, it has been shown recently that endosomally located TLR3, which senses double-stranded RNA, and TLR7, which senses single-stranded RNA, are antiatherogenic in the ApoE −/− mouse model. 9, 10 These findings indicate that specific TLRs can exert both proand antiatherogenic effects, and that signaling from each of these TLRs influences the development of atherosclerosis. TLR9 is an endosomally located TLR, which senses bacterial DNA via recognition of the CpG motif. 11 This receptor can also respond to DNA released from host cells and this response has been linked to both pathology 12 and protection 13 in different inflammatory disease settings. TLR9 is expressed by multiple immune cell types that accumulate in atherosclerotic lesions, including macrophages, plasmacytoid and conventional DCs (pDCs), and B cells. 14, 15 Several lines of evidence suggest that this receptor may also influence development of atherosclerosis. In vitro, TLR9-mediated activation of macrophages with a CpG-containing oligodeoxynucleotide results in increased lipid accumulation and augmented foam cell formation. 16 Furthermore, TLR9 is expressed by pDC within fibrofatty lesions from human atherosclerotic lesions, 17 and ex vivo activation of TLR9 with a CpG-containing oligodeoxynucleotide stimulated interferon (IFN)-α secretion and increased the cytotoxicity of CD4 + T cells toward smooth muscle cells. 17 However, other evidence suggests that TLR9 may be protective against atherosclerosis. For example, TLR9 activation in vitro stimulates interleukin (IL)-10 production by conventional DCs, which can in turn inhibit the expression of IFN-α by pDCs.
18 TLR9 activation has also been shown to stimulate B cells to produce IL-10, which subsequently inhibits CD4 + CD25 − T-cell proliferation. 19 Moreover, TLR9 plays a tolerogenic role in mediating the production of protective self-reactive serum IgM antibodies by peritoneal B-1b cells in lupus-prone mice to control Th17 cell development and autoimmunity. 20 In addition, in the Murphy Roths Large model of murine lupus, TLR9 signaling plays a protective role by modulating the activity of CD4 + CD25
+ regulatory T cells. 13 To define the precise role that TLR9 plays in atherogenesis, we used a newly generated double-knockout C57Bl/6 mouse, in which both TLR9 and ApoE were deleted. These ApoE −/− :TLR9 −/− mice were fed a high-fat diet, and effects on atherosclerotic lesion formation were compared with control ApoE −/− mice. The results suggest that TLR9 has a protective function against atherosclerosis, a finding that is supported by the reduced lesion severity observed after administration of a TLR9-stimulating oligodeoxynucleotide to ApoE −/− mice. Our findings thus suggest that TLR9 agonists may have potential for the treatment of atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Supplement. Figure 1A ). In addition, macrophage accumulation, as revealed by anti-monocytes and macrophage marker-2 staining, was also significantly increased in the ApoE −/− :TLR9 −/− mice (71% increase; P<0.01; Figure 1B ). In contrast, smooth muscle cell content was unaffected (P>0.05; Figure 1C ). The expression of 2 molecules critical for the development of atherosclerosis, vascular cell adhesion molecule-1 and monocyte chemotactic protein-1, 21 was also unaffected by TLR9 deletion (Figure 2A and 2B), as was the size of the necrotic core (P>0.05; Figure 2C ). Importantly, we also confirmed that in ApoE 
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TLR9 Deletion and Atherosclerotic Lesion Characteristics
DCs play key roles in the development of atherosclerosis and may affect the accumulation of CD4 + T cells. 17 We first investigated whether DCs express TLR9 in atherosclerotic plaques. Figure 3C ). Expression of IL-1β was unaffected, whereas tumor necrosis factor (TNF)-α and IL-6 tended to be increased, but the difference did not reach statistical significance (P>0.05; Figure 3C ). As expected, given the increase in macrophage accumulation ( Figure 1B ), CD68 mRNA levels were also increased ( Figure 3C Figure 3B ). Furthermore, TLR9 deletion resulted in a marked 3-fold increase in mRNA expression of TIM-3 (P<0.05; Figure 3C ), a membrane protein expressed during CD4 + Th1 cell differentiation 22 and also on CD11b DCs. 23 Interestingly, TLR9 deficiency was also associated with increased numbers of splenic CD4 + and CD8 + T cells (P<0.05; Figure 3D ) and although there was a tendency for B2 cells to be increased ( Figure 3D ), this was not reflected in any difference in serum levels of IgM between the 2 mouse genotypes (data not shown). Other lymphocyte populations were largely unaffected, and monocyte/macrophage subset proportions did not differ between the 2 mouse genotypes ( Figure IV in the online-only Data Supplement).
TLR9 Deletion and Serum Lipid Levels
To determine whether TLR9 influenced cholesterol homeostasis, we measured total, very LDL/LDL-and high-density lipoprotein (HDL) cholesterol as well as triglycerides in plasma. These were all elevated to a greater extent in ApoE 
TLR9 Agonist Reduces Atherosclerotic Lesion Development
Given the exacerbated disease phenotype of ApoE −/− :TLR9
−/− mice, we next investigated whether a TLR9 agonist demonstrates any therapeutic effect in reducing atherosclerotic lesion development. Eight-week-old ApoE −/− mice fed a high-fat diet were administered either the type B CpG oligodeoxynucleotide TLR9 agonist (oligodeoxynucleotide 1668) or vehicle (PBS) for a total of 8 weeks, and then atherosclerotic lesion size was determined by Oil-Red O staining. This analysis demonstrated that in ApoE −/− mice, oligodeoxynucleotide 1668 administration significantly attenuated atherosclerotic lesion development (P<0.01; Figure 6A ). Moreover, this reduced lesion development occurred in the absence of any changes in serum lipid profiles between the oligodeoxynucleotide 1668 and vehicle-treated mice ( Figure 6B-6F) .
Discussion
It has been demonstrated previously that TLR9 activation can result in both proinflammatory and anti-inflammatory effects in different disease settings. TLR9 contributes to acute pancreatitis in a mouse model, and treatment with a TLR9 antagonist reduced disease severity and attenuated both neutrophil infiltration and interleukin-1β expression. 24 Similarly, TLR9 also promotes glomerular nephritis; deletion of TLR9 attenuated CD4 + T-cell and macrophage infiltration and reduced expression of the proinflammatory cytokines IFN-γ, TNF-α, and IL-1β, as well as the chemokine monocyte chemotactic protein-1. 25 TLR9 has also been reported to promote liver fibrosis 26 and acute hepatoxicity 12 in mouse disease models. In contrast, during liver ischemia/reperfusion injury, necrotic hepatocyte-derived DNA activated conventional DCs via TLR9, thereby increasing their production of IL-10. This, in turn, reduced production of TNF-α, IL-6, and reactive oxygen species by inflammatory monocytes and attenuated ischemia/ reperfusion injury. 27 Similarly, TLR9-mediated increases in DC-derived indoleamine 2,3-dioxygenase protected against experimental autoimmune diabetes mellitus. 28 Thus, the central role of TLR9 in many inflammatory diseases is suggestive of a possible role in atherosclerosis, but available reports would not allow foreseeing the direction of TLR9's involvement, as either pro-or antiatherosclerotic.
In vitro data describing CpG DNA-mediated activation of macrophages stimulating foam cell formation 16, 29, 30 imply that TLR9 might rather contribute to the development of atherosclerosis. However, in contrast to this, our in vivo studies demonstrate that TLR9 has a protective role against atherosclerosis in the ApoE −/− mouse model. Interestingly, similar discrepancies between in vitro proinflammatory effects and overall in vivo atheroprotective effects have been reported for TLR3 and TLR7. 9, 10 These discrepancies between in vitro and in vivo data might be explained by the multitude of cell types that express TLRs and cell-specific differences in the abundance of TLR ligands and thus, in the in vivo setting individual cell type responses might be counteracted by others. Also, various diseases might differ in the overall complex response to TLR signaling. For example, postinterventional vascular remodeling is reduced by the combined blockade of TLR7 and TLR9, 31 whereas genetic deficiency of TLR7, as reported by Salagianni et al, 10 and TLR9, as reported here, causes acceleration of atherosclerosis. Notably, our data are consistent with recent findings indicating an emerging paradigm that endosomally located TLRs (eg, TLR3, TLR7) exert atheroprotection, whereas cell surface-located TLRs (eg, TLR2, TLR4) exert proatherosclerotic effects. [6] [7] [8] [9] [10] 
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(mmol/L) T cells can contribute to the development of a vulnerable atherosclerotic plaque phenotype in the ApoE −/− mouse model by perforin-and granzyme B-mediated apoptosis and promotion of necrotic core formation. 36 However, in the current study, we found that necrotic core size was not different between ApoE −/− and ApoE −/− :TLR9 −/− mice, suggesting that CD8 + T cells in this setting did not significantly contribute to atherosclerotic lesion characteristics. Our data point to a critical role of CD4 + T cells in atherosclerotic lesion development in the ApoE −/− mouse in the absence of TLR9. We found this lymphocyte population to be increased, not only in the spleens of ApoE :TLR9 −/− mice secreted more of the proinflammatory cytokine TNF-α, and less of the anti-inflammatory cytokine IL-10, than did such splenic cells from the control ApoE −/− mice, describe a potential mechanistic link between these lymphocytes and exacerbated atherosclerosis in the ApoE −/− :TLR9 −/− mice. This is of particular interest because TNF-α has long been implicated in macrophage proliferation, 37 which only just recently has been identified as a major contributing factor in atherogenesis. 38 This localized source of macrophages in plaques is consistent with a localized modulatory role of the innate immune system in atherosclerosis.
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In our study, TLR9 deletion also resulted in upregulation of Tim-3 in atherosclerotic lesions. Tim-3 is expressed by both CD11b + DCs and CD4 + Th1 cells, but not CD11b + macrophages. 23 Its increased expression in the atherosclerotic lesions from ApoE −/− :TLR9 −/− mice is consistent with our finding of an increased abundance of these cell populations within lesions. Tim-3 ligation on DCs synergizes with TLRs in promoting inflammatory responses, 23 so it is possible that enhanced Tim-3 expression contribute to the augmented atherosclerosis in the TLR9-deficient mice, possibly via the increase in IFN-α that concomitantly occurred in the lesions of the ApoE −/− :TLR9 −/− mice. This possibility is consistent with a recent study showing that stimulation of TLR9 on DCs reduces IFN-α secretion. 39 Several lines of evidence suggest that the elevation in IFN-α that we observed in atherosclerotic lesions of the TLR9-deficient mice (an increase in the plasma level was not seen, data not shown) can contribute to the augmentation in lesion growth. Low-dose IFN-α treatment accelerated atherosclerosis in LDL receptor-deficient mice. 40 
IFN-α also stimulated Ly6C
hi monocyte migration to sites of inflammation and it also promoted lipid uptake by macrophages and augmented macrophage-derived foam cell formation. 41 Consistent with this proatherosclerotic role of IFN-α is the finding of a recent study, which demonstrated the proatherosclerotic role of pDCs, which are known to be high producers of IFN-α. 42 However, there is also a report identifying pDCs and IFN-α as being atheroprotective, 43 indicating that further studies on the emerging but potentially complex role of DCs in atherosclerosis are needed.
At present, we cannot clearly define which cell type is primarily responding to TLR9 in atherosclerotic lesions, although several lines of evidence suggest that it may be pDCs. Our study indicates that pDCs in atherosclerotic lesions express TLR9. Furthermore, recent studies indicate that high concentrations of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TIR domain containing adapter inducing interferon-β (TRIF) pathway in pDCs; such DCs, for example, prevent airways inflammation. 44, 45 It is possible that such a pathway is also stimulated in atherosclerotic lesions. Unfortunately, there is no specific surface marker that would allow the identification of tolerogenic DCs in atherosclerotic plaques. As to the source of TLR9 stimulatory oligonucleotides, recent studies indicate that DNA complexes on the surface of apoptotic cells are capable of activating TLR9 46 ; apoptotic cells are present in significant numbers in lesions. 47 Although TLR9 activation also stimulates naive B cells to proliferate and differentiate into IgM-secreting cells 48 and synthetic CpG oligodeoxynucleotides are known to augment B-cell activating factor mediated IgG secretion, 49 plasma IgM and IgG levels were unaffected by TLR9 deletion, making it unlikely that an effect on B cells contributes to the atheroprotective effects of TLR9.
Our data raise the intriguing possibility that synthetic TLR9 agonists may represent a novel therapeutic approach in atherosclerosis. Previous studies have shown that the therapeutic potential of CpG oligodeoxynucleotides is likely to be highly dependent on CpG oligodeoxynucleotides type. 50 Interestingly, the same type B CpG oligodeoxynucleotide as used in our study has been shown to ameliorate intestinal inflammation and to decrease the severity of colitis in a mouse model of inflammatory bowel disease. 51 Moreover, type B CpG oligodeoxynucleotides administered to mice before myocardial ischemia followed by reperfusion was able to significantly decrease infarct size and improve cardiac function. 52 Overall, CpG oligodeoxynucleotides are promising drug candidates with many human trials, including phase 3, currently ongoing. 50 It has been shown previously that deletion of TLR4 attenuated the development of atherosclerosis via decreases in IL-12, monocyte chemotactic protein-1, macrophage numbers, and cyclo-oxygenase-2. 6 These effects were discussed as being independent of cholesterol levels. 53 More recently, however, it has been proposed that TLR4 exerts at least part of its proatherosclerotic capacity via an increase in plasma cholesterol levels, specifically in cholesterol-rich VLDL/ LDL particles. 8 Interestingly, this increase in VLDL/LDL cholesterol plasma levels was not associated with changes of HDL cholesterol. Therefore, the proatherosclerotic effects of TLR4 are likely to be associated with the detected proatherogenic increase of VLDL/LDL cholesterol. In contrast, our study shows that the increase in plasma levels of VLDL/LDL cholesterol is paralleled by an increase in HDL cholesterol, which has been shown to be atheroprotective in mice 54 and humans. [55] [56] [57] Thereby the VLDL/LDL:HDL cholesterol ratio, which is seen as strong determinant of cardiovascular risk, [58] [59] [60] remains unchanged. Furthermore, the importance of direct, cholesterol-independent inflammatory mechanisms is further underscored by our demonstration that both CD4 + T-cell depletion and type B CpG oligodeoxynucleotide administration were able to attenuate TLR9-associated lesion development in the absence of any alterations in VLDL/LDL cholesterol plasma levels. In summary, the changes observed in the lipid profile in ApoE −/− :TLR9 −/− mice point to an interesting role of TLR9 in cholesterol metabolism, which warrants further studies. Although our findings suggest a tolerogenic mechanism dependent on TLR9 activation of pDCs as being important in mediating the atheroprotective effects of TLR9, the fact that TLR9 also regulates plasma lipid levels suggests that a lipiddependent mechanism may also contribute. Because DCs are also known to modulate hypercholesterolemia, 61 it is tempting to speculate that TLR9 may also initiate a yet to be identified effect in DCs that regulates hypercholesterolemia.
In summary, this study advances our knowledge of the important but complex role of TLRs in atherosclerosis. Using a genetic and a pharmacological approach, we can demonstrate a protective role of TLR9 in atherosclerosis and we describe the modulation of cell numbers and inflammatory phenotype of CD4 + T cells as potential mechanisms. Moreover, we have identified a novel and attractive therapeutic approach to attenuate progression of atherosclerotic disease based on the use of specific TLR9-activating CpG oligodeoxynucleotides, which belong to a promising drug group that is already in clinical development.
